ClinicalTrials.gg
CompletedNCT07065331APkITAUpdated Oct 14, 2025

A Study of Inhaled AZD8630 in Adolescents With Asthma

A Phase 1 interventional study of AZD8630 and Dry powder inhaler in Asthma, sponsored by AstraZeneca. Completed at 9 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
243rd of 248
10 · median 175
Started
2025
with 12 others
Phase 1
46 of 359
none open now
Registered
344th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 243rd largest by enrollment of the 248 interventional ones that give a count, is one of 13 that started in 2025, is one of 46 in phase 1, and was the 344th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, tolerability, and immunogenicity of single inhaled dose of AZD8630 administered in adolescent participants with asthma as well as the safety and performance of the dry powder inhaler.

Read the detailed description

This is a Phase 1, open label, single dose study that will be conducted in adolescent participants with asthma where the participants will receive AZD8630 administered via dry powder inhaler.

The study will be comprised of:

  • A screening period.
  • A treatment period.
  • A post treatment period.
  • A final Follow-up visit.
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Dry powder inhaler
  • Anti-Thymic stromal lymphopoietin
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Physician prescribed daily use of asthma medication.
  • Pre-bronchodilator (FEV1) ≥ 50% of the predicted normal value.
  • Asthma control questionnaire-5 (ACQ-5) \< 1.5 at Screening and Study Day 1.

Key Exclusion Criteria:

  • History of any disease or disorder.
  • History of any chronic respiratory disorders (except asthma).
  • Acute exacerbation of asthma within 4 weeks of Screening.
  • Life -threatening asthma.
  • Completed treatment for respiratory infection with antibiotics within 4 weeks of Screening.
  • History of acquired or inherited immunodeficiency disorders.
  • Oral immunotherapy, including stable maintenance dose allergen-specific oral immunotherapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    AZD8630

    Participants will receive single inhaled dose of AZD8630 on Day 1 via dry powder inhaler.

    Drug: AZD8630 · Device: Dry powder inhaler

Interventions

  • Single inhaled dose of AZD8630 via dry powder inhaler.

  • DeviceDry powder inhaler

    Single inhaled dose of AZD8630 via dry powder inhaler.

06

What researchers measure

Primary outcomes

  1. Area under the serum concentration-time curve from time zero to 24 hours (AUC0-24)

    The AUC0-24 of AZD8630 after administered as single inhaled dose in adolescent participants with asthma will be evaluated.

    Time frame: Up to Day 9

  2. Maximum observed drug concentration (Cmax)

    The Cmax of AZD8630 after administered as single inhaled dose in adolescent participants with asthma will be evaluated.

    Time frame: Up to Day 9

  3. Time to reach peak or maximum observed concentration (Tmax)

    The Tmax of AZD8630 after administered as single inhaled dose in adolescent participants with asthma will be evaluated.

    Time frame: Up to Day 9

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    The safety and the tolerability of AZD8630 in adolescent participants with asthma will be evaluated.

    Time frame: From screening until Follow-up (Day 9)

  2. Incidences of anti-drug antibodies (ADA) of AZD8630

    The immunogenicity of AZD8630 in adolescent participants with asthma will be evaluated.

    Time frame: Day 1 and Day 9

  3. Number of participants with AEs associated with dry powder inhaler

    The safety and the performance of the dry powder inhaler device in adolescent participants with asthma will be evaluated.

    Time frame: Day 1

  4. Number of participants with dry powder inhaler deficiencies

    The safety and the performance of the dry powder inhaler in adolescent participants with asthma will be evaluated.

    Time frame: Day 1

  5. Number of participants with dose administration confirmation

    The safety and the performance of the dry powder inhaler in adolescent participants with asthma will be evaluated.

    Time frame: Day 1

07

Study locations

9 sites
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Lafayette, Louisiana 70508, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Toledo, Ohio 43617, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Boerne, Texas 78006, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secureresearchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Sep 2025, 3 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 3 months is below that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jul 15, 2025
StartActual
Jun 11, 2025
Primary completionActual
Sep 19, 2025
CompletionActual
Sep 19, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065331
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jun 11, 2025
Primary completion
Sep 19, 2025
Completion
Sep 19, 2025
Last update
Oct 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sunakiment

Start the discussion